AstraZeneca and Daiichi Sankyo’s ENHERTU showed objective response rates of 49% and 56% with 5.4mg/kg and 6.4mg/kg doses respectively in primary analysis ENHERTU provided a median progression-free ...

Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0% and median duration of response of 16.8 months ...

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer The first patient has been dosed in the ...

Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated activity across multiple types of solid cancers — including some that are notoriously difficult to treat— according to findings from the phase 2 ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated ...

First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (“BTD”) to their blockbuster antibody-drug conjugate (ADC), Enhertu, ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. CHICAGO — Enhertu, the antibody-drug conjugate ...

DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...

A course of Enhertu treatment costs £117,857 at the list price, though the NHS can access a discounted rate. Enhertu product sales of $932 million and alliance revenues of $683 million. Get the ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) plus pembrolizumab versus ...